<DOC>
	<DOCNO>NCT03038113</DOCNO>
	<brief_summary>This randomize study conduct two part evaluate safety , tolerability , pharmacodynamics , pharmacokinetics subcutaneous administration RO7062931 . Part 1 include healthy participant Part 2 include participant chronic hepatitis B ( CHB ) . Part 1 adaptive , single-ascending dose study adaptive dose-escalating schedule determine best dose evaluated participant CHB . Part 2 adaptive , parallel multiple-dose study comprise two sub-parts use refine dose dose regimen .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Pharmacokinetics Pharmacodynamics RO7062931in Healthy Volunteers Subjects With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>FOR HEALTHY VOLUNTEERS ONLY PART 1 A Body Mass Index ( BMI ) 18 30 kg/m2 inclusive body weight least 50 kg . Women nonchildbearing potential . A woman consider childbearing potential postmenarcheal reach postmenopausal state undergone surgical sterilization ( removal ovary and/or uterus ) . Men must agree remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure treatment 105 day last dose , agree refrain donate sperm . Nonsmoker ( tobacco contain product ) least 90 day prior dose Day 1 agree remain nonsmoker study . FOR CHB PARTICIPANTS ONLY PART 2 : A BMI 18 32 kg/m2 inclusive . Chronic hepatitis B ( HBV ) infection . Positive test HBsAg 6 month prior randomization HBsAg titer ≥ 10^3 IU/mL screening . On entecavir , tenofovir , adefovir telbivudine treatment least 6 month prior randomization remain stable treatment study . HBV deoxyribonucleic acid ( DNA ) ≤ 90 IU/mL least precede 6 month . Screening laboratory value ( hematology , chemistry , urinalysis ) obtain 56 day prior first study treatment within normal range . Liver biopsy , fibroscan® equivalent test obtain within past 6 month demonstrate liver disease consistent chronic HBV infection without evidence bridge fibrosis cirrhosis Women nonchildbearing potential . A woman consider childbearing potential postmenarcheal reach postmenopausal state undergone surgical sterilization ( removal ovary and/or uterus ) . Men must agree remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure treatment 105 day last dose , agree refrain donate sperm . FOR HEALTHY VOLUNTEERS ONLY PART 1 : History drug alcohol abuse dependence previous 6 month . Positive urine drug alcohol screen Day 1 . Positive result hepatitis B ( HBV ) , hepatitis C ( HCV ) , human immunodeficiency virus ( HIV ) 1 2 . Confirmed blood pressure rest pulse rate outside accept range . Participation investigational drug device study within 90 day prior screen . Donation blood 500 mL within three month prior screen . Any major illness within one month , febrile illness within two week precede screen visit . Alcohol consumption 2 standard drink per day average . FOR CHB PARTICIPANTS ONLY PART 2 : History evidence bleed esophageal varix . Decompensated liver disease . History suspicion hepatocellular carcinoma alpha fetoprotein ( AFP ) ≥ 13 ng/mL Screening History evidence medical condition associate chronic liver disease HBV infection . Documented history evidence metabolic liver disease within one year randomization document history infection hepatitis D virus . Positive test hepatitis A ( IgM antiHAV ) , hepatitis C , HIV . Organ transplantation . Significant acute infection clinically significant illness within 2 week randomization . Abnormal renal function . Participation investigational drug device study within 30 day prior randomization . Donation loss blood 500 mL within 3 month prior start study medication . Administration blood product within 3 month randomization . History evidence alcohol abuse ( consumption 2 standard drink per day average ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>